Impact of treatment-related cardiac toxicity on lymphoma survivors: an institutional approach for risk reduction and management.
Despite improvements in treatment and overall survival rates, survivors of lymphoma may have long-term and late effects. Given the immense risk for cardiac disease after treatment for Hodgkin lymphoma and non-Hodgkin lymphoma, healthcare providers should focus on prevention of secondary adverse effects. The Dana-Farber Cancer Institute has been working to develop guidelines to address the cardiotoxicities that impact the lymphoma survivor population.
Walsh
Michele C
MC
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. michele_walsh@dfci.harvard.edu
D000970:Antineoplastic Agents / Q000009:adverse effects*; D006331:Heart Diseases / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008223:Lymphoma / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy; D017410:Practice Guidelines as Topic; D011878:Radiotherapy / Q000009:adverse effects*; D012307:Risk Factors
D000970:Antineoplastic Agents